Safety and efficacy of combined dual antiplatelet therapy and factor VIII prophylaxis in patients with haemophilia A after acute coronary syndrome
Haemophilia · 2024-03 · 30 (2) · 336-344
DOI: 10.1111/hae.14963 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, online erschienen am 20.02.2024. Verfasst von Pasquale Agosti und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Hemophilia A, Thrombosis, Hemostatics. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Ministry of Health-Bando Ricerca Corrente, Ministero della Salute.
Abstract (Originalsprache)
Introduction
The increased life expectancy of patients with haemophilia A (HA) has led to a growing prevalence of cardiovascular risk factors and events. There is still scarce evidence on the safety and appropriate duration of dual antiplatelet therapy (DAPT) after acute coronary syndrome (ACS) in HA patients.
Aim
We describe our experience on the clinical management of Italian HA patients after ACS.
Methods
Nine patients with congenital HA treated with DAPT after a revascularization procedure performed for ACS have been enrolled and followed at the Angelo Bianchi Bonomi Haemophilia and Thrombosis Center in Milan between 2005 and September 2022. The safety and efficacy of DAPT with or without FVIII prophylaxis were assessed.
Results
Ten ACS events occurred in the nine HA patients (four mild and five severe). All events were treated with percutaneous transluminal coronary angioplasty with deployment of 1 to 3 drug‐eluting stents followed by DAPT for 1–12 months. All patients except one were treated with FVIII prophylaxis during DAPT aimed at achieving FVIII trough levels ≥20–30 IU/dL. DAPT was effective in all cases in preventing early ACS recurrence, with only a late recurrence. We observed two clinically relevant non‐major bleeds (one in a patient without FVIII prophylaxis) and three minor bleeds. No venous thrombosis occurred.
Conclusion
The long‐term secondary antithrombotic prevention consisting of DAPT and FVIII prophylaxis achieving a trough level of 20–30 IU/dL can be effective and safe in HA patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Haemophilia and Thrombosis Center, Milan, Italy.
ORCID-Profile: Sara Arcudi, Roberta Gualtierotti, Flora Peyvandi
Förderung
- Ministry of Health-Bando Ricerca Corrente
- Ministero della Salute
Zitieren
APA
Agosti, P., Siboni, S. M., Ciavarella, A., Arcudi, S., Boggio, F., Gualtierotti, R., & Peyvandi, F. (2024). Safety and efficacy of combined dual antiplatelet therapy and factor VIII prophylaxis in patients with haemophilia A after acute coronary syndrome. Haemophilia, 30(2), 336-344. https://doi.org/10.1111/hae.14963
Vancouver
Agosti P, Siboni SM, Ciavarella A, Arcudi S, Boggio F, Gualtierotti R, et al. Safety and efficacy of combined dual antiplatelet therapy and factor VIII prophylaxis in patients with haemophilia A after acute coronary syndrome. Haemophilia. 2024;30(2):336-344. doi:10.1111/hae.14963
BibTeX
@article{Agosti2024,
author = {Agosti, Pasquale and Siboni, Simona Maria and Ciavarella, Alessandro and Arcudi, Sara and Boggio, Federico and Gualtierotti, Roberta and Peyvandi, Flora},
title = {Safety and efficacy of combined dual antiplatelet therapy and factor VIII prophylaxis in patients with haemophilia A after acute coronary syndrome},
journal = {Haemophilia},
year = {2024},
volume = {30},
number = {2},
pages = {336--344},
doi = {10.1111/hae.14963}
}
EUVIMED